A Phase 2 Multi-center, Open-label, Single Arm Study of Nab-sirolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment with mTOR Inhibitors